Showing results (61-70 of 139) with videos related to

Sort By:
Pageof 14
Molecular Oncology|February 10, 2016
Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancerFrancesca Riva, Oleksii I Dronov, Dmytro I Khomenko, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 8, 2018
Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study)Aziz Zaanan, Emmanuelle Samalin, Thomas Aparicio, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 20, 2020
Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR)David Tougeron, Pierre Michel, Astrid Lièvre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2023
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyChristophe Tournigand, Thierry André, Emmanuel Achille, et al.
Health and Quality of Life Outcomes|June 3, 2014
Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 studyMomar Diouf, Benoist Chibaudel, Thomas Filleron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2003
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR studyChristophe Tournigand, Thierry André, Emmanuel Achille, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trialThierry Andre, Philippe Colin, Christophe Louvet, et al.
Pageof 14